{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:42Z","timestamp":1793406882717,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of Malaya Special Research Fund","award":["Project No.: BK006-2016"],"award-info":[{"award-number":["Project No.: BK006-2016"]}]},{"name":"University of Malaya Special Research Fund","award":["BKS067-2017"],"award-info":[{"award-number":["BKS067-2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10620-019-5477-1","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T10:02:33Z","timestamp":1548410553000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct02964715","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lee-Lee","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireene Ratna","family":"Vethakkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Raihan","family":"Nik Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Mahadeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah-Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"5477_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"5477_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/jgh.12204","volume":"28","author":"WK Chan","year":"2013","unstructured":"Chan WK, Tan AT, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Non-alcoholic fatty liver disease in diabetics\u2014prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol. 2013;28:1375\u20131383.","journal-title":"J Gastroenterol Hepatol"},{"key":"5477_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s00125-016-3952-1","volume":"59","author":"K Cusi","year":"2016","unstructured":"Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016;59:1112\u20131120.","journal-title":"Diabetologia"},{"key":"5477_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/07853890.2010.518623","volume":"43","author":"G Musso","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617\u2013649.","journal-title":"Ann Med"},{"key":"5477_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547\u2013555.","journal-title":"Gastroenterology"},{"key":"5477_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u2013690.","journal-title":"Lancet"},{"key":"5477_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136\u2013142.","journal-title":"Diabet Med"},{"key":"5477_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u20132128.","journal-title":"N Engl J Med"},{"key":"5477_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115\u20131122.","journal-title":"Diabetes Care"},{"key":"5477_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717\u2013725.","journal-title":"Diabetes Care"},{"key":"5477_CR11","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jgh.12557","volume":"29","author":"WK Chan","year":"2014","unstructured":"Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470\u20131476.","journal-title":"J Gastroenterol Hepatol"},{"key":"5477_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/gut.2007.126417","volume":"56","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Yoneda M, Fujita K, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330\u20131331.","journal-title":"Gut"},{"key":"5477_CR13","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u20132023.","journal-title":"Hepatology"},{"key":"5477_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1539\/joh.45.335","volume":"45","author":"E Anuurad","year":"2003","unstructured":"Anuurad E, Shiwaku K, Nogi A, et al. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health. 2003;45:335\u2013343.","journal-title":"J Occup Health"},{"key":"5477_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome\u2014a new worldwide definition. Lancet. 2005;366:1059\u20131062.","journal-title":"Lancet"},{"key":"5477_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2008-1410","volume":"94","author":"PE Cryer","year":"2009","unstructured":"Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709\u2013728.","journal-title":"J Clin Endocrinol Metab"},{"key":"5477_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u20131321.","journal-title":"Hepatology"},{"key":"5477_CR18","doi-asserted-by":"publisher","first-page":"e0160789","DOI":"10.1371\/journal.pone.0160789","volume":"11","author":"TG St Pierre","year":"2016","unstructured":"St Pierre TG, House MJ, Bangma SJ, et al. Stereological analysis of liver biopsy histology sections as a reference standard for validating non-invasive liver fat fraction measurements by MRI. PLoS ONE. 2016;11:e0160789.","journal-title":"PLoS ONE"},{"key":"5477_CR19","doi-asserted-by":"publisher","first-page":"1147e1145","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147e1145\u20131159e1145.","journal-title":"Gastroenterology"},{"key":"5477_CR20","doi-asserted-by":"publisher","first-page":"1940e1948","DOI":"10.1016\/j.cgh.2017.04.016","volume":"15","author":"C Wah Kheong","year":"2017","unstructured":"Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940e1948\u20131949e1948.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5477_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246\u2013255.","journal-title":"Eur J Pharmacol"},{"key":"5477_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","volume":"7","author":"S Qiang","year":"2015","unstructured":"Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7:104.","journal-title":"Diabetol Metab Syndr"},{"key":"5477_CR23","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313:E563\u2013E576.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5477_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","volume":"8","author":"T Jojima","year":"2016","unstructured":"Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016;8:45.","journal-title":"Diabetol Metab Syndr"},{"key":"5477_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u20131114.","journal-title":"Diabetes Care"},{"key":"5477_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13300-017-0355-3","volume":"9","author":"PCH Lee","year":"2018","unstructured":"Lee PCH, Gu Y, Yeung MY, et al. Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther. 2018;9:285\u2013295.","journal-title":"Diabetes Ther"},{"key":"5477_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53:140\u2013151.","journal-title":"J Gastroenterol"},{"key":"5477_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","volume":"42","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42:25\u201332.","journal-title":"Diabetes Metab"},{"key":"5477_CR29","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10620-012-2098-3","volume":"57","author":"P Charatcharoenwitthaya","year":"2012","unstructured":"Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:1925\u20131931.","journal-title":"Dig Dis Sci"},{"key":"5477_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","volume":"29","author":"VW Wong","year":"2009","unstructured":"Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009;29:387\u2013396.","journal-title":"Aliment Pharmacol Ther"},{"key":"5477_CR31","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","volume":"56","author":"A Takeda","year":"2017","unstructured":"Takeda A, Irahara A, Nakano A, et al. The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin. Intern Med. 2017;56:2739\u20132744.","journal-title":"Intern Med"},{"key":"5477_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep4.1019","volume":"1","author":"N Akuta","year":"2017","unstructured":"Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46\u201352.","journal-title":"Hepatol Commun"},{"key":"5477_CR33","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801\u20131808.","journal-title":"Diabetes Care"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-5477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-019-5477-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-5477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:09:24Z","timestamp":1628597364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-019-5477-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5477"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-5477-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}